Q1 2018 Data Report

The Q1 2018 Data Report details industry-specific statistics and trends from more than 861 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide. Key features of the report include total financings for the sector, partnerships and other deals, clinical trial information, major clinical data events, and ARM's current legislative and regulatory priorities.

Highlighted findings from the Q1 2018 data report include:

  • Globally, companies active in gene and cellular therapies and other regenerative medicines raised more than $3.8 billion in the first quarter of 2018, a 135% increase from Q1 2017. The report also includes financial data broken out by technology type and financing type.
  • There were 959 clinical trials underway worldwide at the close of the first quarter of 2018, with more than 53 percent of those in oncology and nearly 10 percent in cardiovascular disorders. The report also includes figures on clinical trials by phase and indication, as well as by technology type.

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers, and clinical data events.

To view and download previously released data reports and ARM presentations, please click here.

To download the report, please fill out the form below.

The report includes standalone graphics highlighting key data points, available below. Please right-click on the desired file type (.jpg or .png) to save the image to your computer.

 

[.jpg]   [.png]

[.jpg]   [.png]

[.jpg]   [.png]

[.jpg]   [.png]

[.jpg]   [.png]

SaveSave

SaveSave